Cidara Therapeutics, Inc. (CDTX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à San Diego, CA, United States. Le PDG actuel est Jeffrey L. Stein.
CDTX a date d'introduction en bourse 2015-04-15, 38 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $5.61B.
Cidara Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing long-acting anti-infective treatments for infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel echinocandin antifungal designed to treat and prevent invasive fungal infections such as candidemia and invasive candidiasis, which carry high mortality rates. Cidara also leverages its Cloudbreak platform to develop conjugate therapies for preventing and treating viral infections, including influenza, RSV, HIV, and COVID-19. Founded in 2012 and based in San Diego, California, the company was formerly known as K2 Therapeutics before rebranding to Cidara Therapeutics in 2014.
